Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2012-08-29 Interim / Quarterly Rep…
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Half Yearly Report and Accounts 36 pages 364.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Cyclopharm Limited Appendix 4D - Half Year Report' and references the half year ended 30 June 2012. It contains detailed financial data including revenues, losses, segment performance, and outlook. It includes financial statements such as Statement of Comprehensive Income, Statement of Financial Position, and Notes to the Financial Statements. The document is 15,000 characters long, indicating it is a full report rather than a brief announcement. Appendix 4D is a regulatory form used in Australia for half-year financial reporting, which aligns with an Interim / Quarterly Report. The content includes substantive financial data and analysis for a period shorter than a full fiscal year, consistent with the definition of an Interim / Quarterly Report (IR). Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2012
2012-08-29 English
Cyclopharm to Establish Operations in Queensland 2 pages 97.4KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement dated 24 August 2012 from Cyclopharm Limited, addressed to the Australian Securities Exchange. It announces a new operational agreement to establish a cyclotron manufacturing facility in Queensland. The content focuses on a strategic business development and partnership agreement, describing future plans and expected capital costs. There are no financial statements, quarterly or annual results, nor any regulatory certifications or voting results. The document is relatively short (4639 characters) and reads as a corporate announcement about a capital project and business expansion. This fits best under Capital/Financing Update (CAP) as it relates to company financing and capital expenditure plans for a new facility. It is not an Annual Report, Interim Report, or Earnings Release, nor is it a regulatory filing or management change announcement.
2012-08-23 English
Cyclopharm Files Claim Against ANSTO 2 pages 93.7KB
Legal Proceedings Report Classification · 95% confidence The document is a company announcement dated 28 June 2012 from Cyclopharm Limited. It details the filing of a legal claim against ANSTO's subsidiary Petnet Pty Ltd, including references to specific legal statutes and the Federal Court of Australia proceedings. The content focuses on the initiation of legal action and background information about the company and its products. There are no financial statements, earnings data, or management discussion of financial results. The document is not a report but an announcement of legal proceedings. Therefore, it fits best under Legal Proceedings Report (LTR). The document length is 4643 characters, which is sufficient for a substantive announcement rather than a brief notice or report publication announcement.
2012-06-27 English
Update on Share Consolidation 2 pages 156.2KB
Share Issue/Capital Change Classification · 95% confidence The document is an announcement dated 8 June 2012 from Cyclopharm Limited to the Australian Securities Exchange. It provides an update on the completion of a share consolidation (every 5 shares consolidated into 1 share) approved at a General Meeting on 24 May 2012. It states that new holding statements have been dispatched and trading will resume on 12 June 2012. The document also includes background information about the company and its business but contains no financial statements, detailed financial data, or regulatory filings. The document length is 4089 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on a capital structure change (share consolidation) and the resumption of trading, which fits the category of Share Issue/Capital Change announcements. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2012-06-07 English
AGM Presentation Audio Broadcast 2 pages 157.3KB
AGM Information Classification · 95% confidence The document is titled 'AGM Presentation: Audio broadcast' and references an audio presentation for the 2012 Annual General Meeting (AGM) of Cyclopharm Limited. It provides a link to listen to the presentation and includes background information about the company and its operations. The document does not contain financial statements or detailed financial analysis but rather serves as presentation material related to the AGM. The length is under 5,000 characters and it is clearly a presentation shared during the AGM event. Therefore, it fits the category of AGM Information (AGM-R).
2012-05-27 English
AGM Presentation 32 pages 1.8MB
AGM Information Classification · 95% confidence The document is titled 'Annual General Meeting' and dated 24 May 2012. It contains a Chairman's Address, Managing Director's Review, business strategy, segmental overviews, financial highlights for 2011, outlook for 2012, and other presentation materials typically shared during an AGM. The content includes detailed business updates, financial performance summaries, and future plans, consistent with materials presented at an Annual General Meeting. There is no indication that this is a full Annual Report (10-K) or an earnings release, nor is it a regulatory filing or certification. The length (15,000 characters) and detailed content support that this is the AGM presentation material itself, not just an announcement of a report. Therefore, the document fits the category of AGM Information (AGM-R).
2012-05-23 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.